{"quoteSummary":{"result":[{"defaultKeyStatistics":{"maxAge":1,"priceHint":{"raw":2,"fmt":"2","longFmt":"2"},"enterpriseValue":{"raw":9014491136,"fmt":"9.01B","longFmt":"9,014,491,136"},"forwardPE":{},"profitMargins":{"raw":-1.18469,"fmt":"-118.47%"},"floatShares":{"raw":75352902,"fmt":"75.35M","longFmt":"75,352,902"},"sharesOutstanding":{"raw":105569000,"fmt":"105.57M","longFmt":"105,569,000"},"sharesShort":{},"sharesShortPriorMonth":{},"heldPercentInsiders":{},"heldPercentInstitutions":{},"shortRatio":{},"shortPercentOfFloat":{},"beta":{"raw":-0.688099,"fmt":"-0.69"},"morningStarOverallRating":{},"morningStarRiskRating":{},"category":null,"bookValue":{"raw":-15.26,"fmt":"-15.26"},"priceToBook":{},"annualReportExpenseRatio":{},"ytdReturn":{},"beta3Year":{},"totalAssets":{},"yield":{},"fundFamily":null,"fundInceptionDate":{},"legalType":null,"threeYearAverageReturn":{},"fiveYearAverageReturn":{},"priceToSalesTrailing12Months":{},"lastFiscalYearEnd":{"raw":1459382400,"fmt":"2016-03-31"},"nextFiscalYearEnd":{"raw":1522454400,"fmt":"2018-03-31"},"mostRecentQuarter":{"raw":1459382400,"fmt":"2016-03-31"},"earningsQuarterlyGrowth":{},"revenueQuarterlyGrowth":{},"netIncomeToCommon":{"raw":-4003545600,"fmt":"-4B","longFmt":"-4,003,545,600"},"trailingEps":{"raw":-33.661,"fmt":"-33.66"},"forwardEps":{},"pegRatio":{},"lastSplitFactor":"2/1","lastSplitDate":{"raw":1392854400,"fmt":"2014-02-20"},"enterpriseToRevenue":{"raw":2.667,"fmt":"2.67"},"enterpriseToEbitda":{"raw":-5.101,"fmt":"-5.10"},"52WeekChange":{"raw":-0.32311976,"fmt":"-32.31%"},"SandP52WeekChange":{"raw":0.12668931,"fmt":"12.67%"},"lastDividendValue":{},"lastCapGain":{},"annualHoldingsTurnover":{}},"earnings":{"maxAge":86400,"earningsChart":{"quarterly":[]},"financialsChart":{"yearly":[{"date":2013,"revenue":{"raw":10735153000,"fmt":"10.74B","longFmt":"10,735,153,000"},"earnings":{"raw":537076000,"fmt":"537.08M","longFmt":"537,076,000"}},{"date":2014,"revenue":{"raw":13247928000,"fmt":"13.25B","longFmt":"13,247,928,000"},"earnings":{"raw":703225000,"fmt":"703.23M","longFmt":"703,225,000"}},{"date":2015,"revenue":{"raw":8384648000,"fmt":"8.38B","longFmt":"8,384,648,000"},"earnings":{"raw":-2339021000,"fmt":"-2.34B","longFmt":"-2,339,021,000"}},{"date":2016,"revenue":{"raw":3379396488,"fmt":"3.38B","longFmt":"3,379,396,488"},"earnings":{"raw":-4003545666,"fmt":"-4B","longFmt":"-4,003,545,666"}}],"quarterly":[{"date":"2Q2015","revenue":{"raw":1370588500,"fmt":"1.37B","longFmt":"1,370,588,500"},"earnings":{"raw":-745530500,"fmt":"-745.53M","longFmt":"-745,530,500"}},{"date":"3Q2015","revenue":{"raw":1088432000,"fmt":"1.09B","longFmt":"1,088,432,000"},"earnings":{"raw":-732656000,"fmt":"-732.66M","longFmt":"-732,656,000"}},{"date":"4Q2015","revenue":{"raw":1046916000,"fmt":"1.05B","longFmt":"1,046,916,000"},"earnings":{"raw":-707425000,"fmt":"-707.42M","longFmt":"-707,425,000"}},{"date":"1Q2016","revenue":{"raw":357685000,"fmt":"357.69M","longFmt":"357,685,000"},"earnings":{"raw":-1537349000,"fmt":"-1.54B","longFmt":"-1,537,349,000"}}]},"financialCurrency":"INR"},"summaryProfile":{"address1":"BSEL Tech Park","address2":"312, C Wing Sector-30(A) Opp. Vashi Railway Station","city":"Navi Mumbai","zip":"400705","country":"India","phone":"91 22 6794 4000","fax":"91 22 6794 4001","website":"http://www.sharonbio.com","industry":"Drug Manufacturers - Major","sector":"Healthcare","longBusinessSummary":"Sharon Bio-Medicine Limited, a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs), formulations, and toxicology products. The company provides APIs that cover various therapeutic areas, including anti-fungal, diabetic, Alzheimer, hypertensive, depressant, bacterial, protozoal, psychotic, and diarrhoeal areas, as well as cardiovascular, muscle relaxation, pro-kinetic, veterinary, and NSAID areas. Its intermediate product line targets various API/end uses, such as ketoconazole, itraconazole, phase transfer catalyst, lansoprazole, trimetazidine and its salts, and sertraline HCL. The company also offers formulations in the therapeutic segments of oncology, antibiotics, dermatology, liquid orals, soft gelatin capsules, and suppositories. In addition, it provides preclinical toxicology services related to animals; formulation and analytical method development, and chemical process development and scale up services; stability monitoring services for the product shelf life; and DMF and dossier preparation services. The company was incorporated in 1989 and is based in Navi Mumbai, India.","companyOfficers":[],"maxAge":86400},"financialData":{"maxAge":86400,"currentPrice":{"raw":5.09,"fmt":"5.09"},"targetHighPrice":{"raw":63.0,"fmt":"63.00"},"targetLowPrice":{"raw":63.0,"fmt":"63.00"},"targetMeanPrice":{"raw":63.0,"fmt":"63.00"},"targetMedianPrice":{"raw":63.0,"fmt":"63.00"},"recommendationMean":{},"recommendationKey":"none","numberOfAnalystOpinions":{"raw":1,"fmt":"1","longFmt":"1"},"totalCash":{"raw":101563000,"fmt":"101.56M","longFmt":"101,563,000"},"totalCashPerShare":{"raw":0.854,"fmt":"0.85"},"ebitda":{"raw":-1767128832,"fmt":"-1.77B","longFmt":"-1,767,128,832"},"totalDebt":{"raw":8363190784,"fmt":"8.36B","longFmt":"8,363,190,784"},"quickRatio":{"raw":0.572,"fmt":"0.57"},"currentRatio":{"raw":1.17,"fmt":"1.17"},"totalRevenue":{"raw":3379396608,"fmt":"3.38B","longFmt":"3,379,396,608"},"debtToEquity":{},"revenuePerShare":{"raw":28.414,"fmt":"28.41"},"returnOnAssets":{},"returnOnEquity":{},"grossProfits":{"raw":-1100697058,"fmt":"-1.1B","longFmt":"-1,100,697,058"},"freeCashflow":{},"operatingCashflow":{"raw":-419838560,"fmt":"-419.84M","longFmt":"-419,838,560"},"earningsGrowth":{},"revenueGrowth":{"raw":-0.726,"fmt":"-72.60%"},"grossMargins":{"raw":-0.32571,"fmt":"-32.57%"},"ebitdaMargins":{"raw":-0.52291,"fmt":"-52.29%"},"operatingMargins":{"raw":-0.58215,"fmt":"-58.21%"},"profitMargins":{"raw":-1.18469,"fmt":"-118.47%"},"financialCurrency":"INR"}}],"error":null}}